Page 2 - Jb Chemicals & Pharmaceuticals

Vinay Rajani of HDFC Securities suggests buying these stocks on July 31

JB Chemical's price has surpassed the crucial triple top resistance placed in the range of Rs 1,920-1,930. Stock has broken out from broken out from the consolidation, which held for last four months.

JB Pharma aims to grow its revenue by 12-14% in the next two years

JB Pharma plans to maintain its presence in cardiology, focusing on hypertension, heart failure, and lipid-lowering treatments

PE firm KKR considers selling controlling stake in JB Pharma: Report

The US private equity firm is looking to hire financial advisers to help evaluate a sale of its 53.8% stake in the Mumbai-based company, the people said

JB Pharma CEO attributes 3.5% of company's growth to new introductions

"We are growing at 16 per cent, compared to the Indian Pharma Market (IPM) growth of 8 per cent, and a 12 per cent growth of the market which we cover," Chopra said

JB Chemicals & Pharma Q3 results: Net profit rises 26% to Rs 134 crore

JB Chemicals & Pharmaceuticals on Tuesday said its net profit rose 26 per cent to Rs 134 crore for the third quarter ended December 2023. The company reported a net profit of Rs 106 crore in the October-December period of the last fiscal. Revenue increased to Rs 845 crore in the third quarter compared to Rs 793 crore in the year-ago period, JB Pharma said in a statement. "Our focus on growing the domestic business ahead of the market continues, as reflected in the Q3 performance. The business once again stands out in this quarter," JB Pharma CEO and Wholetime Director Nikhil Chopra stated. In the international division, the formulations business is stable, he added. "Our approach to develop progressive portfolios is on track, resulting in a positive impact for the exports branded generics business," Chopra said. Shares of the company settled 1.18 per cent higher at Rs 1,724 apiece on the BSE.

JB Chemicals buys opthalmology brands from Novartis for Rs 964 crore

JB Chemicals and Pharmaceuticals shall offer employment to the impacted associates working on this portfolio, it said today. JB Chemicals shares ended on BSE at Rs 1466 apiece, down marginally

JB Chemicals & Pharmaceuticals PAT grows 35% to Rs 142 crore in Q1

JB Chemicals & Pharmaceuticals Ltd on Wednesday reported a 35 per cent increase in profit after tax at Rs 142 crore in the first quarter ended June 30, 2023. The company had posted a Profit After Tax (PAT) of Rs 105 crore in the same quarter last fiscal, JB Chemicals & Pharmaceuticals (JB Pharma) said in a statement. Revenue in the quarter under review stood at Rs 896 crore as against Rs 785 crore in the year-ago period, a growth of 14 per cent, it added. Domestic formulations business stood at Rs 489 crore, a growth of 17 per cent. Revenue from international business crossed the Rs 400 crore mark for the first time in a quarter, the company said. "Our domestic business continued its growth trajectory through strong momentum in our chronic portfolio and acquired assets. Our big brands, especially in the chronic segment, continue to outpace the market and have reached new milestones," JB Pharma CEO and Whole Time Director Nikhil Chopra said. The CDMO (Contract Development and ..

Kansai Nerolac, Canara Bank, Mankind Pharma among top stocks to watch today

Stock to Watch on Tuesday, May 9: Canara Bank's net profit rose 90.6 per cent year-on-year (YoY) at Rs 3,175 crore in Q4FY23

JB Chemicals & Pharmaceuticals to consider sub-division of equity shares

A final decision on this will be taken during the board meeting to be held on 24 May 2023

JB Chemicals & Pharma Q2 PAT up 13% to Rs 111 cr; revenue at Rs 809 cr

JB Chemicals & Pharmaceuticals has reported 13 per cent rise in profit after tax at Rs 111 crore for the second quarter ended September 30, 2022. The drug firm had logged a profit after tax (PAT) of Rs 98 crore in July-September period of previous fiscal year. Revenue rose to Rs 809 crore in the period under review as compared with Rs 593 crore in the year-ago quarter, it said in a statement. "Our market-beating performance in domestic business was sustained through growth in our organic portfolio, with big brands getting bigger; and significant demand acceleration in acquired brands which have seamlessly transitioned in a short period," company CEO and Wholetime Director Nikhil Chopra said. The momentum in the international business continued across markets, with all three of the company's verticals performing well, he added. "Our strategic focus on key brands, segments and geographies is resulting in a consistent, sustained revenue growth. "And this growth, along with ...

Vinay Rajani of HDFC Securities expects markets to remain bullish for now

Among individual stocks, the technical analyst recommends buying JK Tyre and J.B.Chemicals & Pharma.

JB Chem gets board approval to acquire Dr Reddy's 4 brands for Rs 98 cr

JB Chemicals & Pharmaceuticals on Thursday said its board has approved a proposal to acquire four paediatric brands from Dr Reddy's Laboratories for about Rs 98 crore. The company's board at its meeting held on June 29, has considered and approved the acquisition of a portfolio of brands, for use sales within India, from Dr Reddy's Laboratories, the drug maker said in a regulatory filing. The company has inked a pact with Dr Reddy's Laboratories to acquire four of its brands -- Z&D, Pedicloryl, Pecef and Ezinapi -- for the India market, it added. All four brands are focused on the paediatric segment in the country with a total covered market size of Rs 1,800 crore as per IQVIA data, JB Chemicals & Pharmaceuticals said. The combined sales of these brands stood at around Rs 33 crore for FY 2021-22, it added. The acquisition, which will be funded primarily through long-term debt, will be completed in the next few working days, the drug firm stated.

KKR-backed JB Chemicals bets big on lozenges and probiotic products

JB Chemicals now plan to enter new areas like sleep disorders, sexual wellness, motion sickness, and immunity apart, from the conventional areas like cough, sore throat, etc.

JB Chemicals & Pharmaceuticals posts Rs 119 crore profit April-June

Drug firm JB Chemicals & Pharmaceuticals on Thursday reported a consolidated net profit of Rs 119.05 crore for the quarter ended on June 30, 2021. The company had posted a net profit of Rs 119.50 crore for the corresponding period of the previous fiscal, JB Chemicals & Pharmaceuticals said in a filing to BSE. Consolidated revenue from operations of the company stood at Rs 606 crore for the quarter under consideration. It was Rs 522.3 crore for the same period a year ago, it added. "The organisation continues its strong performance well in the first quarter of the financial year. On the domestic front, we are one of the fastest growing companies in the industry," JBCPL CEO and Wholetime Director Nikhil Chopra said. While demand trends in international business continue to be volatile (given the COVID situation); the company's key markets like the US, South Africa have outperformed and even Russia/ CIS are seeing gradual signs of revival, he added. Shares of JB Chemicals & ..

JB Chemicals & Pharmaceuticals Q4 net profit jumps two-fold to Rs 101 cr

Drug firm JB Chemicals & Pharmaceuticals on Monday reported a two-fold jump in consolidated net profit to Rs 100.81 crore for the quarter ended March 2021 on account of robust sales. The company had posted a net profit of Rs 50.07 crore for the corresponding period of the previous fiscal year, JB Chemicals & Pharmaceuticals said in a regulatory filing. Consolidated revenue from operations stood at Rs 528 crore for the quarter under consideration. It was Rs 444 crore for the same period a year ago, it added. For the full fiscal 2020-21, the net profit of the company was Rs 449 crore as against Rs 272 crore for the previous year, the filing said. Revenue from operations for the fiscal year ended March 2021 stood at Rs 2,043 crore. It was Rs 1,775 crore in FY20. The board of directors has recommended a final dividend of Rs 8 per equity share of face value of Rs 2 for the financial year 2020-21, it added. "Our financial performance for FY21 has been encouraging in one of the most .

JB Chemicals: New launches, market share gains to drive growth

Key chronic segments have helped the JB Chemicals outperform the Indian pharma market.

JB Chemicals surges 12%, hits record high on strong Q3 performance

The board has declared interim dividend of Rs 8.50 per equity share of face value of Rs 2 (425 per cent) for FY21

KKR-backed JB Chemicals scouts for acquisitions, plans to revamp business

With the former Cipla head at the helm, JB Chemicals now plans to diversify into paediatrics and respiratory

JB Chemicals rallies 19% in two days on strong June quarter numbers

In the past six months, the stock has soared 82 per cent against 25 per cent rise in the S&P BSE Sensex.

JB Chemicals surges 16%, hits all-time high as Q1 net profit jumps 92%

The company's revenue came in at Rs 522.28 crore, up 17 per cent against Rs 446.11 crore in the corresponding quarter of the previous fiscal.